CVS Health Is Maintained at Overweight by Piper Sandler
CVS Health Analyst Ratings
Piper Sandler Maintains CVS Health(CVS.US) With Buy Rating, Cuts Target Price to $64
Piper Sandler Sticks to Their Buy Rating for CVS Health (CVS)
TD Cowen Maintains CVS Health(CVS.US) With Buy Rating, Raises Target Price to $80
Palantir Price Target Raised To $75 By Dan Ives Amid 288% YTD Surge: Analyst Calls 2025 A 'Primetime' Year For AI
CVS Health Analyst Ratings
Truist Financial Maintains CVS Health(CVS.US) With Buy Rating, Announces Target Price $67
Truist Financial Remains a Buy on CVS Health (CVS)
Truist Lowers Price Target on CVS Health to $67 From $76, Keeps Buy Rating
Leerink has lowered the target price for cvs health to $57.
Leerink Partners Maintains CVS Health(CVS.US) With Hold Rating, Cuts Target Price to $57
Evercore Maintains CVS Health(CVS.US) With Buy Rating, Maintains Target Price $75
CVS Health: Strategic Board Enhancements and Undervaluation Drive Buy Rating
Leerink Adjusts Price Target on CVS Health to $57 From $63, Maintains Market Perform Rating
Wells Fargo Upgrades CVS Health to Overweight From Equalweight, Adjusts Price Target to $66 From $60
RBC Capital lowered CVS Health's target price to $58.
CVS Health Is Maintained at Outperform by RBC Capital
CVS Health Analyst Ratings
RBC Capital Maintains CVS Health(CVS.US) With Buy Rating, Cuts Target Price to $58